Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons

Bagsværd, Denmark, 15 May 2024 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse.

The company’s board members, executives and their associated persons have reported the transactions to Novo Nordisk and have given Novo Nordisk power of attorney on their behalf to publish trading in Novo Nordisk shares by the company’s board members, executives and their associated persons.

Please find below a statement of such trading in shares issued by Novo Nordisk.

  Details of the person discharging managerial responsibilities/person closely associated
a) Name of the Board member/Executive/Associated Person Martin Holst Lange  
2 Reason for the notification  
a) Position/status Executive Vice President  
b) Initial notification/Amendment Initial notification  
3 Details of the issuer  
a) Name Novo Nordisk A/S  
b) LEI 549300DAQ1CVT6CXN342  
4 Details of the transaction(s)  
a) Description of the financial instrument,type of instrument, Shares   
  Identification code Novo Nordisk B DK0062498333  
b) Nature of the transaction Sale of shares  
c) Price(s) and volume(s)          
  Price(s) Volume(s)    
  DKK 915.50 9,000 shares    
         
         
d) Aggregated information
  • Aggregated volume
  • Price
9,000 sharesDKK 8,239,500.00  
e) Date of the transaction 2024-05-14  
f) Place of the transaction Nasdaq Copenhagen  

Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases, built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 63,400 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn and YouTube.

Contacts for further information

Media:  
Ambre James-Brown +45 3079 9289 abmo@novonordisk.com  Liz Skrbkova (US) +1 609 917 0632 lzsk@novonordisk.com
Investors:  
Daniel Muusmann Bohsen +45 3075 2175 dabo@novonordisk.com  Jacob Martin Wiborg Rode +45 3075 5956 jrde@novonordisk.com 
David Heiberg Landsted +45 3077 6915 dhel@novonordisk.com  Mark Joseph Root (US) +1 848 213 3219 mjhr@novonordisk.com 
Sina Meyer +45 3079 6656 azey@novonordisk.com  Frederik Taylor Pitter +45 3075 8259 fptr@novonordisk.com
Ida Melvold Gjøsund+45 3077 5649idmg@novonordisk.com  

Company announcement No 42 / 2024

Attachment

  • CA240515-insider-trading
Novo Nordisk (TG:NOV)
Historical Stock Chart
Von Mai 2024 bis Jun 2024 Click Here for more Novo Nordisk Charts.
Novo Nordisk (TG:NOV)
Historical Stock Chart
Von Jun 2023 bis Jun 2024 Click Here for more Novo Nordisk Charts.